The first of hundreds of lawsuits filed by consumers who claim the Abilify antipsychotic caused compulsive behavior has been scheduled for trial in June after a federal judge tossed a bid by drug makers to dismiss the litigation.

The bellwether trial would be the first to put a sustained spotlight on the extent to which the widely used medication has caused patients to succumb to uncontrollable urges to engage in impulsive gambling, shopping, eating, or sex. About 700 lawsuits have been filed in federal court in Florida and dozens more were filed in other states, mostly in New Jersey.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.